ADC Therapeutics caps year of milestones by building bridge to China via Hillhouse-backed Overland’s debut deal

Hillhouse-backed Overland’s first deal — the establishment of JV with four cancer programs from Swiss biotech ADC Therapeutics — underscores the start-up’s intent to leverage the “biotech ecosystem” its parent firm has established to bring first-in-class therapies and other innovative Western therapies to China.

The joint venture, Overland ADCT BioPharma (CY) Ltd., will develop and commercialize loncastuximab tesirine (informally, “Lonca”) from ADC Therapeutics S.A. (NYSE:ADCT), a humanized mAb against CD19 that is under FDA review, and three other pyrrolobenzodiazepine-based antibody-drug conjugates in Greater China and Singapore. ...